BioCardia Inc (BCDA) shares surged by a staggering 95% on Thursday, reaching $4.30 per share, following the US Food and Drug Administration’s (FDA) approval for the company’s Morph DNA Steerable Introducer product family.
This groundbreaking product family is designed to streamline the introduction of medical instruments, such as catheters and guidewires, into the peripheral vasculature and heart chambers during various cardiovascular and interventional procedures.
BioCardia’s CEO, Peter Altman, emphasized the significance of this achievement, highlighting that earlier versions of the Morph product have been successfully used in approximately 12,000 procedures. The new Morph DNA family is anticipated to further enhance the experience for physicians and patients.
Initially developed to enhance BioCardia’s cell therapy procedures, the company now expects the Morph DNA product line to yield positive outcomes across a wider range of advanced interventional procedures.
For investors interested in acquiring BCDA stock, several avenues are available. Traditional brokerage platforms allow for the purchase of shares or fractional shares. Alternatively, investors can gain exposure to BCDA through exchange-traded funds (ETFs) that hold the stock or by allocating to a strategy in their 401(k) that targets mutual funds or other instruments within the Health Care sector.
BCDA’s stock performance over the past year has seen a significant range, reaching a 52-week high of $23.25 and a 52-week low of $1.96.
